Translational Medicine
taking innovation from lab to patient

Focusing on medical innovations in oncology

ORYX’ investment and development strategy bridges the gap for new therapies between academic research and the pharmaceutical industry.
Since its inception in 2007, the company has been identifying and financing promising translational projects. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need.

Helping patients fight cancer

Building on medical and scientific excellence

ORYX has built an outstanding network of scientific and clinical advisors, including Nobel laureate Prof. Harald zur Hausen. The in-licensing of well-chosen projects from the German Cancer Research Center (DKFZ), Heidelberg gave birth to the company and led to a close and permanent collaboration with the scientists of DKFZ.